Biomarin Pharmaceutical (BMRN) - FREE Research Report

Bienaime Jean Jacques who is Chief Executive Officer at Biomarin Pharmaceutical sold 3,000 shares at $66.76 on Oct. 15, 2013. Following this transaction, the Chief Executive Officer owned 45,740 shares meaning that the stake was reduced by 6.16% with the 3,000 share transaction.

The shares most recently traded at $72.33, up $5.57, or 7.7% since the insider transaction. Historical insider transactions for Biomarin Pharmaceutical go as follows:

  • 12-Week # shares sold: 4,066
  • 24-Week # shares sold: 36,416

The average volume for Biomarin Pharmaceutical has been 1.4 million shares per day over the past 30 days. Biomarin Pharmaceutical has a market cap of $10.3 billion and is part of the health care sector and drugs industry. Shares are up 49.61% year to date as of the close of trading on Friday.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Currently there are 10 analysts that rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BMRN - FREE

TheStreet Quant Ratings rates Biomarin Pharmaceutical as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and feeble growth in the company's earnings per share. Get the full Biomarin Pharmaceutical Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

If you liked this article you might like

Broad Gains Push Wall Street Higher, S&P 500 on Track for Fifth Day of Gains

Pipelines Shut, Arkema Plant Explodes - 5 Things You Must Know

Investors Brace for Market Open After 'Catastrophic' Texas Flooding

Here Comes Another Jobs Report

Quant Ratings Upgrades Ciena to a 'Buy,' but the Charts Look Mixed